GLPwatch
Papers (9189)
Page 146 of 154, ranked by citation count.
- Discovery and identification of semaphorin 4D as a bioindicator of high fracture incidence in type 2 diabetic mice with glucose control.
- [Semaglutide for the Management of type 2 Diabetes: Clinical Evidence, Cardioprotective Effects, and Guidelines].
- A bifunctional anti-PCSK9 scFv/Exendin-4 fusion protein exhibits enhanced lipid-lowering effects via targeting multiple signaling pathways in HFD-fed mice.
- Oral Semaglutide: Balancing Promising Therapeutics with Adverse Effects and Access Barriers.
- Assessment of Thermal and Photolytic Stress Effects on the Stability of Primary Structure of Synthetic Liraglutide Using LC-HRMS/MS.
- Semaglutide in routine clinical practice: interesting news from real-world evidence.
- Update: Pediatric Diabetes.
- THE AUTHORS RESPOND.
- Letter to the Editor: Can semaglutide result in a tangible cardiovascular benefit in recipients of liver transplants?
- Comparison of Pediatric and Adult Glucagon-Like Peptide-1 Receptor Agonist Exposures Reported To United States Poison Centers, 2017-2024.
- Semaglutide, Obesity-Related Heart Failure, and Type 2 Diabetes.
- What are the cardiovascular effects of the newer classes of drugs for type 2 diabetes?
- Reply.
- Major adverse cardiovascular and limb events caused by tirzepatide in patients with type 2 diabetes at high cardiovascular risk: A comparison with sitagliptin.
- Liraglutide reduced a composite renal outcome at a median 4 y in patients with type 2 diabetes and high CV risk.
- Tirzepatide in dermatology: cutaneous adverse events, emerging therapeutic roles, and cosmetic implications - A comprehensive review.
- Liraglutide Modulates Zinc Release and Improves Mitochondrial Function in Insulin-Resistant Senescent Cardiomyocytes.
- Design, synthesis, and biological evaluation of long-acting glucagon-like peptide-1 (GLP-1) conjugates modified with dual fatty acids and a proline-alanine-serine (PAS) polypeptide.
- Liraglutide promotes diabetic corneal epithelial and nerve regeneration by suppressing oxidative stress via the PI3K/AKT signalling pathway.
- Choice of first injectable therapy in type 2 diabetes.
- Effect of pH, buffers, molarity, and temperature on solution state degradation of semaglutide using LC-HRMS: A preformulation protocol for peptide drug delivery.
- Balancing oral sequential absorption barriers of semaglutide-loaded nanoparticles by optimization of surface glycocholic acid density.
- [The Beneficial Effects of Switching from Dipeptidyl Peptidase-4 Inhibitors to Dulaglutide on Plasma Glucose and Hemoglobin A1c Levels: A Case Report of Four Patients with Type 2 Diabetes].
- Clinical Manifestations of Semaglutide Overdose: A Case Study.
- In symptomatic peripheral artery disease with T2D, semaglutide increased maximum walking distance at 1 y.
- The future use of liraglutide: implications of the LEAD-2 study for treatment guidelines in type 2 diabetes.
- [Effect of liraglutide on interleukin-1β expression in the pancreatic islets of OLETF rats].
- Algorithm-Based Common Microcirculatory Framework for Monitoring and Visualizing the Integrated Pancreatic Microcirculation in Type 2 Diabetes Mellitus Mice.
- Therapeutic potential of targeting ceramide for early cardiometabolic lipotoxicity in vivo study.
- Switching from subcutaneous to oral semaglutide in type 2 diabetes: A prospective study.
- New Drugs 2019, part 1.
- Larotrectinib-associated withdrawal symptoms resolved following initiation of GLP-1 receptor agonist: a case report.
- Which Drug Will "Lead" in Reducing Cardiac Events Among Heart Failure Patients With Diabetes?
- The cost-effectiveness of subcutaneous semaglutide 2.4 mg in the management of people living with obesity and prediabetes in England.
- Pharmacokinetic evaluation of fixed-ratio combination of insulin degludec and liraglutide in the treatment of type 2 diabetes.
- Semaglutide, Obesity-Related Heart Failure, and Type 2 Diabetes.
- [The extra-glycemic effects of liraglutide: focus on cardiometabolic markers].
- Semaglutid: Ein wirksames Medikament zur Gewichtsabnahme.
- [Glucagon-like peptide-1 receptor agonists].
- In high-risk type 2 diabetes, adding oral semaglutide to standard care reduced MACE at a mean 48 mo.
- [Pharmacological and clinical profiles of a human GLP-1 analogue, liraglutide (Victoza(®))].
- Modulation of circulating extracellular vesicles by antihyperglycemic therapies: A pilot randomized controlled trial.
- Neuroprotective Effects of Liraglutide and/or Rivastigmine Combination on the Rat Hippocampus.
- Depression, cognition, and GLP-1 receptors: Heterogeneity and therapeutic prospects.
- Cost-Effectiveness of Incretin Therapies: A Canadian Lens on Diabetes, Obesity, and Emerging Indications.
- Estimation of Interventional Effects in Clinical Trials With a Repeatedly Measured Mediator.
- Comment on Nauck et al. Effects of Liraglutide Compared With Placebo on Events of Acute Gallbladder or Biliary Disease in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events in the LEADER Randomized Trial. Diabetes Care 2019;42:1912-1920.
- [GLP-1 agonist supports weight loss].
- [Pharmacotherapy for obesity].
- In patients with type 2 diabetes and high CV risk, liraglutide reduced a composite CV outcome at a median 3.8 y.
- [Role of exendin-4 in cardiovascular diseases].
- [GLP-1 receptor agonists : impact on diabetic kidney disease].
- Real-World Evidence of Long-Term Dulaglutide Use: Sustained Glycemic and Weight Improvements Beyond Three Years.
- Peptide Mapping Using Multienzyme Digestion Strategies Integrated with LC-HRMS Workflow: A Case Study.
- [GLP-1 agonists - new kid on the block in nephrology].
- Lithium toxicity following a change from semaglutide to tirzepatide for weight loss management.
- Calories to satiation-A new predictor of anti-obesity therapy outcome?
- Factors influencing patient preferences for obesity pharmacotherapy: The triangulation of semi-structured interviews, photovoice study and focus group discussions.
- Dual-sensitive gelatin-coated chitosan microparticles for targeted semaglutide pulmonary delivery: a novel approach to enhancing anti-inflammatory and anti-fibrotic effects.
- Pharmacosimilars In Obesity Medicine: Informed Choice, Appropriate Choice.